Contribution of platelets and the vessel wall to the antithrombotic effects of a single bolus injection of Fab fragments of the antiplatelet GPIIb/IIIa antibody 7E3 in a canine arterial eversion graft preparation.

The contribution of platelets and the vessel wall to the antithrombotic effects of a single intravenous bolus injection of 0.8 mg/kg Fab fragments of the monoclonal antiplatelet glycoprotein IIb/IIIa receptor antibody 7E3 (7E3-Fab), combined with continuous heparin anticoagulation (100 U/kg bolus and 50 U/kg per hour), was studied in a canine preparation consisting of an everted (inside out) carotid arterial segment that had been inserted into a transected femoral artery. In all 6 control dogs without antibody, persistent or transient eversion graft occlusion occurred during an initial 2-hour observation period, and 5 of the 6 grafts were occluded at 24 hours. In 6 dogs given 7E3-Fab 24 hours before receiving an everted carotid artery segment from a donor dog, cyclic occlusion and reflow occurred in all dogs, whereas the grafts were patent at the end of a 2-hour observation period in 5 of the 6 dogs (P = .056 versus control). When transferred back to the donor dogs, the patient eversion segments showed brief periods of cyclic occlusion and reflow within 2 hours in 3 of 5 dogs (P = .034 versus control), whereas all of the 5 eversion segments were patent at 24 hours (P < .005 versus control).(ABSTRACT TRUNCATED AT 250 WORDS)

[1]  H. Gold,et al.  Time course of the effects of a single bolus injection of F(ab')2 fragments of the antiplatelet GPIIb/IIIa antibody 7E3 on arterial eversion graft occlusion, platelet aggregation, and bleeding time in dogs. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[2]  B. Sobel,et al.  Coronary thrombolysis in perspective : principles underlying conjunctive and adjunctive therapy , 1993 .

[3]  Frans Van de Werf,et al.  An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.

[4]  E. Bates,et al.  Sustained inhibition of the vessel wall‐platelet interaction after deep coronary artery injury by temporary inhibition of the platelet glycoprotein llb/llla receptor , 1992 .

[5]  H. Gold Conjunctive antithrombotic and thrombolytic therapy for coronary-artery occlusion. , 1990, The New England journal of medicine.

[6]  D. Collen Coronary thrombolysis: streptokinase or recombinant tissue-type plasminogen activator? , 1990, Annals of internal medicine.

[7]  C. Legrand,et al.  Studies on the mechanism of expression of secreted fibrinogen on the surface of activated human platelets. , 1989, Blood.

[8]  W J Penny,et al.  Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor. , 1989, Circulation.

[9]  Sarah Parish,et al.  Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. , 1988, Journal of the American College of Cardiology.

[10]  H. Gold,et al.  Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. , 1988, Circulation.

[11]  A. Giles,et al.  Guidelines for the use of Animals in Biomedical Research , 1987, Thrombosis and Haemostasis.

[12]  Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico. LONG-TERM EFFECTS OF INTRAVENOUS THROMBOLYSIS IN ACUTE MYOCARDIAL INFARCTION: FINAL REPORT OF THE GISSI STUDY , 1987, The Lancet.

[13]  G. Courtois,et al.  Expression of intracellular fibrinogen on the surface of stimulated platelets. , 1986, European journal of biochemistry.

[14]  J. Mustard,et al.  Development of Nonthrombogenicity of Injured Rabbit Aortas Despite Inhibition of Platelet Adherence , 1986, Arteriosclerosis.

[15]  B. Coller,et al.  Inhibition of dog platelet function by in vivo infusion of F(ab')2 fragments of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor. , 1985, Blood.

[16]  Gary Halvorson,et al.  Randomized trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction: Verstraete M, Bory M, Erbel R, et al Lancet 842–847 Apr 13, 1985 , 1985 .

[17]  V. Fuster,et al.  Balloon angioplasty. Natural history of the pathophysiological response to injury in a pig model. , 1985, Circulation research.

[18]  R. W. Brower,et al.  RANDOMISED TRIAL OF INTRAVENOUS RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS INTRAVENOUS STREPTOKINASE IN ACUTE MYOCARDIAL INFARCTION Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator , 1985, The Lancet.

[19]  M J Davies,et al.  Plaque fissuring--the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. , 1985, British heart journal.

[20]  H. S. Mueller,et al.  The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.

[21]  M. Fiorotto,et al.  OEDEMA OF MALNUTRITION , 1982, The Lancet.

[22]  S. Moore,et al.  Platelet interaction with damaged rabbit aorta. , 1979, Laboratory investigation; a journal of technical methods and pathology.

[23]  E. Veys,et al.  HL-A AND INFECTIVE SACROILEITIS , 1974 .

[24]  D. Wolfe,et al.  Nonparametric Statistical Methods. , 1974 .

[25]  M. Friedman,et al.  The pathogenesis of a coronary thrombus. , 1966, The American journal of pathology.